Quarterly Statement of Operations and Other Comprehensive Loss (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Dec. 31, 2021 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
||||||
| Quarterly Financial Information Disclosure [Abstract] | ||||||||||||||||
| Revenue | $ 288,963 | $ 288,898 | $ 265,362 | $ 266,446 | $ 117,594 | $ 74,462 | $ 57,478 | $ 71,293 | $ 1,109,669 | $ 320,827 | $ 79,272 | |||||
| Claims expense | (266,404) | (264,283) | (238,764) | (247,552) | (104,026) | (51,298) | (40,384) | (23,917) | (1,017,003) | (219,625) | (25,120) | |||||
| Clinical care delivery expense | (16,543) | (18,505) | (21,649) | (23,927) | (24,957) | (17,038) | (16,013) | (11,823) | (80,624) | (69,831) | (42,134) | |||||
| Platform & application expenses | (4,508) | (5,074) | (6,567) | (13,748) | (10,681) | (4,852) | (12,472) | (4,718) | (29,897) | (32,723) | (32,209) | |||||
| Research & development expenses | (11,256) | (23,008) | (27,577) | (17,314) | (14,365) | (25,195) | (12,667) | (16,246) | (79,155) | (68,473) | (80,538) | |||||
| Sales, general & administrative expenses | (53,311) | (54,474) | (64,503) | (55,649) | (73,176) | (39,257) | (43,753) | (30,986) | (227,937) | (187,172) | (90,687) | |||||
| Impairment expense | (38,599) | (647) | (24,820) | 0 | 0 | 0 | 0 | 0 | (64,066) | 0 | 0 | |||||
| Depreciation and amortization expenses | (2,610) | (2,456) | (3,906) | (3,078) | (4,503) | (2,659) | (1,310) | (713) | (12,050) | (9,185) | (3,955) | |||||
| Premium deficiency reserve income / (expense) | 7,538 | 21,518 | 9,123 | (6,868) | (48,199) | 2,870 | (25) | (1,179) | 31,311 | (46,533) | (5,639) | |||||
| Loss from operations | (96,730) | (58,031) | (113,301) | (101,690) | (162,313) | (62,967) | (69,146) | (18,289) | (369,752) | (312,715) | (201,010) | |||||
| Interest expense | (9,307) | (8,255) | (9,192) | (5,982) | (8,971) | (1,684) | (1,309) | (1,083) | (32,736) | (13,047) | (4,029) | |||||
| Interest income | 374 | 284 | 128 | 255 | 295 | 2 | 14 | 14 | 1,041 | 325 | 610 | |||||
| Loss on settlement of warrants | 0 | (22) | (2,375) | 0 | 0 | 0 | 0 | 0 | (2,397) | 0 | 0 | |||||
| Gain on fair value remeasurement | 2,770 | 11,249 | 99,957 | 78,773 | 239,195 | 0 | 0 | 0 | 192,749 | [1] | 239,195 | [1] | 0 | [1] | ||
| Exchange (loss) / gain | 2,225 | (4,848) | (7,350) | (447) | 1,270 | (396) | 482 | (573) | (10,420) | 783 | (2,836) | |||||
| Gain on sale of subsidiary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,917 | 0 | 3,917 | 0 | |||||
| Share of net loss on equity method investments | 0 | 0 | 0 | 0 | (1,046) | (1,017) | (821) | (455) | 0 | (3,339) | (1,124) | |||||
| Net loss from operations before income taxes | (100,668) | (59,623) | (32,133) | (29,091) | 68,430 | (66,062) | (70,780) | (16,469) | (221,515) | (84,881) | (208,389) | |||||
| Tax benefit / (provision) | 554 | (280) | (199) | (9) | (1,043) | (7) | 2,501 | (8) | 66 | 1,443 | (4,639) | |||||
| Net loss | $ (100,114) | $ (59,903) | $ (32,332) | $ (29,100) | $ 67,387 | $ (66,069) | $ (68,279) | $ (16,477) | $ (221,449) | $ (83,438) | $ (213,028) | |||||
| ||||||||||||||||
| X | ||||||||||
- Definition Clinical Care Delivery Expense No definition available.
|
| X | ||||||||||
- Definition Gain (Loss) On Settlement Of Derivative Liability No definition available.
|
| X | ||||||||||
- Definition Platform And Application Expenses No definition available.
|
| X | ||||||||||
- Definition Premium Deficiency Reserve Income (Expense) No definition available.
|
| X | ||||||||||
- Definition Remeasurement, Gain (Loss) On Financial Instruments No definition available.
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|